Trial Profile
A phase IIIb, multi-center, open-label, study of EVERolimus (RAD001)in combination with EXemestane in post-menopausal women with EStrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer - EVEREXES
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms EVEREXES
- Sponsors Novartis Pharmaceuticals
- 01 Jul 2021 Results reporting the final safety and efficacy outcomes from the EVEREXES trial. published in the Breast Cancer Research and Treatment
- 23 May 2019 Status changed from active, no longer recruiting to completed.
- 11 Jan 2019 Status changed from recruiting to active, no longer recruiting.